2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 260-262
Mechanisms of adaptation to intrinsic metabolic and proteostatic stress during normal hematopoiesis and malignant transformation include induction of chronic endoplasmic reticulum stress, rewiring of tRNA modifications and metabolic precursor transporters, and aberrant activation of metabolic programs downstream of cell surface molecules, creating lineage-specific targetable dependencies in lymphoid malignancies.
Technology and Procedures, Omics Technologies, Gene Editing, Profiling, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, CML, Study Population, Human
PAPER

490 Human lymphoid preleukemia converges on targetable inflammatory and metabolic programs

Miguel Quijada-Alamo, PhD, Grace Freed2, Nikita Poddar, MS3, Saul Carcamo, PhD4, Persephone Fiore5, Ke Wang, PhD6, Mimi Zhang, MS7, Lois M. Kelly, PhD8, Clifford Chao, MD9, Isabella Martinez10, Subrina Autar11, Shayan Saniei12, Levan Mekerishvili13, Zinedine Hoque14, Joann Arandela15, Joseph Tripodi, PhD16, Vesna Najfeld, PhD17, Ilaria Iacobucci, PhD18, Qingsong Gao, PhD19, Charles G. Mullighan, MBBS (Hons), MSc, MD20, Hannah Levavi, MD21, Zhihong Chen, PhD22, Bridget Kelly Marcellino, MD, PhD23, Franco Izzo, PhD24, Dan Hasson, PhD25, Elvin Wagenblast, PhD26
1 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute Bioinformatics for Next Generation Sequencing (BiNGS) Core, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute Bioinformatics for Next Generation Sequencing (BiNGS) Core, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Division of Pediatric Hematology-Oncology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 Division of Hematology and Medical Oncology, Department of Medicine and Meyer Cancer Center, Weill Cornell Medicine, New York, United States, New York Genome Center, New York, United States, Physiology, Biophysics and Systems Biology Graduate Program, Weill Cornell Medicine, New York, United States, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, United States
14 Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, United States
15 Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, United States
16 Department of Pathology and Medicine, Icahn School of Medicine at Mount Sinai, New York, United States, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
17 Department of Pathology and Medicine, Icahn School of Medicine at Mount Sinai, New York, United States, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
18 Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
19 Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
20 Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
21 Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, United States
22 Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, United States
23 Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, United States
24 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
25 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Tisch Cancer Institute Bioinformatics for Next Generation Sequencing (BiNGS) Core, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
26 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Division of Pediatric Hematology-Oncology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, United States, Mindich Child Health & Development Institute, Icahn School of Medicine at Mount Sinai, New York, United States, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States

Clonal hematopoiesis has defined myeloid pre-malignant hematopoietic stem cell (HSC) states years before transformation, but no analogous preleukemic state exists for lymphoid malignancy. Indirect evidence supports this: concordant fusions with discordant secondary lesions in monozygotic twins; fusions backtracked to neonatal blood spots years before diagnosis; and Philadelphia-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL) patients who clear minimal residual disease (MRD) by IG/TR sequencing yet remain positive for their driver fusion. Together, they implicate a silent, HSC-associated founder clone in B-ALL that has not been characterized and can be involved in relapse. BCR::ABL1 fusion, the hallmark of Ph+ disease and whose isoforms p190 and p210 preferentially drive B-ALL and chronic myeloid leukemia (CML), offers a tractable system to define this state.

We used CRISPR/Cas9 to induce endogenous BCR::ABL1 p190 or p210 translocations into primary human CD34+ hematopoietic stem and progenitor cells (HSPCs) from fetal liver, cord blood, and pediatric or adult bone marrow and xenotransplanted the edited cells to ask how developmental context shapes disease (n=170 genotype-verified xenografts). CML-like transformation, marked by granulo/monocytic expansion and a CD34+CD26+ stem-like population, occurred exclusively with p210 in adult bone marrow HSPCs. In every context, both isoforms instead expanded a CD34+CD10+CD19high lymphoid progenitor population that did not show enhanced self-renewal capacity by secondary limiting dilution transplantation, identifying this as a preleukemic state and only transformable by additional mutations such as IKZF1 loss.

We next performed integrated single-cell RNA and ATAC sequencing (>200,000 cells) to define the basis for this developmental restriction. Adult HSCs showed selective myeloid-lineage priming and elevated chromatin accessibility at CEBP-family motifs relative to fetal HSCs, further amplified by BCR::ABL1 p210. Transcriptomic comparison of early- and late-development p210 HSCs nominated PTEN as selectively downregulated in the adult, myeloid-permissive state. Sequential CRISPR knockout of PTEN and p210 induction in primary fetal liver HSPCs conferred, upon xenotransplantation, myeloid expansion and CML-like features to otherwise myeloid-transformation-refractory fetal HSPCs, linking PTEN loss to adult-restricted CML transformation.

In parallel, single-cell multi-omics resolved the lymphoid preleukemic progenitor expansion as a transcriptional and epigenetically distinct ProB VDJ state, marked by upregulation of TNFα and IFNγ. B cell receptor sequencing revealed that this population was polyclonal rather than clonally expanded, and remained arrested at an immature stage of differentiation, consistent with continuous output from the mutant HSC rather than a transformed subclone. We next used fluorescence lineage-tracing to co-transplant wild-type and BCR::ABL1-edited cells within the same xenografts, showing by subsequent scRNA-seq that wild-type HSCs exposed to the BCR::ABL1+ preleukemic population acquired inflammatory signatures, demonstrating non-cell-autonomous remodeling of the normal bone marrow niche by ProB preleukemic cells.

We then asked whether the preleukemic HSC itself could be targeted. It was metabolically distinct, with increased oxidative phosphorylation (OXPHOS), confirmed by higher ATP-linked respiration and mitochondrial mass. This same OXPHOS-high HSC state was also present in BCR::ABL1+ HSCs from Ph+ B-ALL samples (n=6). Treating BCR::ABL1-edited xenografts with metformin as an OXPHOS inhibitor, reduced the mutant preleukemic clone without altering normal hematopoiesis. Notably, metformin reduced the BCR::ABL1+ clone in sorted CD34+CD38-CD10-CD19- HSCs from Ph+ patients with multi-lineage involvement (n=3). This program was not unique to BCR::ABL1: an endogenous IL7R-mutant humanized model of Ph-like B-ALL generated the same preleukemic state and OXPHOS dependence, and this signature extended to several other B-ALL subtypes of multipotent origin.

Together, these data functionally define a human lymphoid preleukemic state, show that developmental-specific chromatin priming and oncogenic signaling jointly determine whether BCR::ABL1 yields B-ALL or CML, and identify OXPHOS as a conserved, targetable dependency of the preleukemic HSC reservoir, offering a strategy to eliminate the persistent preleukemic clone in molecular MRD-positive B-ALL patients.
Miguel Quijada-Alamo, PhD: No relevant conflicts of interest to declare.